Hereditary papillary renal carcinoma: Pathology and pathogenesis

Contributions to Nephrology

Volumn 128, Issue , 1999, Pages 11-27

  Schmidt, Laura ^a   Lubensky, Irina ^b   Linehan, W M ^b   Zbard, Berton ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ALLELE; AMINO ACID SEQUENCE; ANIMAL; GENE EXPRESSION; GENETIC DISORDER; GENETICS; HUMAN; KIDNEY TUMOR; MOUSE; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, PAPILLARY; GENE EXPRESSION; GENETIC DISEASES, INBORN; HUMANS; KIDNEY NEOPLASMS; MICE; MUTATION; PROTO-ONCOGENE PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 0033258502     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059982     Document Type: Article

References (40)

1. Thoenes W, Storkel S, Rumpelt HJ: Histopathology and classification of renal tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125-143.
2. Kovacs G: Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol 1989;134:27-34.
3. Delahunt B, Eble JN: Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-544.
4. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H: Chromosomal imbalances in papillary renal cell carcinoma: Genetic differences between histological subtypes. Am J Pathol 1998;153:1467-1473.
5. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS: Papillary (chromophil) renal cell carcinoma: Histomorphological characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997;21:621-635.
6. Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM: Hereditary papillary renal cell carcinoma. J Urol 1994;151:561-566.
7. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G, Bergerheim USR, Pettersson S, Amin M, Hurley K, Linehan WM: Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol 1995;153:907-912.
8. Zbar B, Lerman M: Inherited carcinomas of the kidney. Adv Cancer Res 1998;75:163-201.
9. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, Scherer S, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui L-C, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
10. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan, WM, Zbar B: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998;58:1719-1722.
11. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HPH, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B: Novel mutations in the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-2350.
12. Weterman MAJ, Wilbrink M, Geurts van Kessel A: Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 1996;93:15294-15298.
13. Weterman MA, Wilbrink M, Janssen I, Janssen HA, van den Berg E, Fisher SE, Craig I, Geurts Van Kessel A: Molecular cloning of the papillary renal cell carcinoma-associated translocation (X; 1)(p11;q21) breakpoint. Cytogenet Cell Genet 1996;75:2-6.
14. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J, Cooper CS: Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997;15:2233-2239.
15. Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, Ross M, Linehan WM, Birdsall S, Shipley J, Cooper CS: The t(X;1) (p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 1996;5:1333-1338.
16. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res 1993;62:89-124.
17. Li FP, Decker H-J H, Zbar B, Stanton VP, Kovacs G, Seizinger B, Aburantani H, Sandberg AA, Berg S, Hosoe S, Brown R: Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3:8 translocation. Ann Intern Med 1993;118:106-111.
18. Schmidt L, Li F, Brown RS, Berg S, Chen F, Wei M-W, Tory K, Lerman MI, Zbar B: Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1995;1:191-196.
19. Bodmer D, Eleveld MJ, Ligtenberg MJ, Weterman MA, Janssen BA, Smeets DF, de Wit PE, van den Berg A, van den Berg E, Koolen MI, Geurts van Kessel A: An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet 1998;62:1475-1483.
20. van den Berg A, van der Veen AY, Hulsbeek MM, Kovacs G, Gemmill RM, Drabkin HA, Buys CH: Defining the position of the breakpoint of the constitutional t(3;6) occurring in a family with renal cell carcinoma. Genes Chromosomes Cancer 1995;12:224-228.
21. Teh BT, Giraud S, Sari NF, Hii SI, Bergerat JP, Larsson C, Limarcher JM, Nicol D: Familial non-VHL non papillary clear-cell renal cancer. Lancet 1997;349:848-849.
22. Weirich G, Glenn G, Junker K, Merino M, Storkel S, Lubensky I, Choyke P, Pack S, Amin M, Walther MM, Linehan WM, Zbar B: Familial renal oncocytoma: Clinicopathological study of 5 families. J Urol 1998;160:335-340.
23. Bugert P, Kovacs G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 1996;149:2081-2088.
24. Zhuang Z, Park WS, Pack S, Schmidt L, Vortmeyer AO, Pak E, Pham T, Weil RJ, Candidus S, Lubensky IA, Linehan WM, Zbar B, Weirich G: Trisomy 7-harbouring non-random duplication of the mutant Met allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-69.
25. Fischer J, Palmedo G, von Knobloch R, Bugert P, Prayer-Galetti T, Pagano F, Kovacs G: Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumors. Oncogene 1998;17:733-739.
26. Glukhova L, Goguel AF, Chuboda I, Angevin E, Pavon C, Terrier-Lacombe MJ, Meddeb M, Escudier B, Bernheim A: Overrepresentation of 7q31 and 17q in renal cell carcinomas. Genes Chromosomes Cancer 1998;22:171-178.
27. Comoglio PM, Vigna E: Structure and functions of the HGF receptor (c-Met); in Jirtle R (ed): Liver Regeneration and Carcinogenesis. New York, Academic Press, 1995, pp 51-70.
28. Hartmann G, Weidner KM, Schwartz H, Birchmeier W: The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase Met requires intracellular action of Ras. J Biol Chem 1994;269:21936-21939.
29. Santos O, Barros E, Yang X, Matsumoto K, Nakamura T, Park M, Nigam S: Involvement of hepatocyte growth factor in kidney development. Dev Biol 1994;163:525-529.
30. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C: Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373:699-702.
31. Maina F, Casagranda F, Audero E, Simeone A, Comoglio P, Klein RA, Ponzetto C: Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996;87:531-542.
32. Bardelli A, Pugliese L, Comoglio PM: 'Invasive-growth' signaling by the Met/HGF receptor. The hereditary renal carcinoma connection. Biochem Biophys Acta 1997;1333:M41-M51.
33. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM: Tyrosines 1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994;9:49-57.
34. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio P:Amultifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-271.
35. Ponzetto C, Zhen Z, Audero E, Mania F, Bardelli A, Basile ML, Giordano S, Narsimhan R, Comoglio P: Specific uncoupling of Grb2 from the Met receptor. Cell 1996;271:14119-14123.
36. Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF: Signaling requirements for oncogenic forms of the MET tyrosine kinase receptor. Oncogene 1998;17:2691-2700.
37. Jeffers M, Rong S, vande Woude G: Hepatocyte growth factor/scatter factor-MET signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-513.
38. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude G: Activating mutations for the MET tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997;94:11445-11450.
39. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF: The mutationally activated MET receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998;95:14417-14422.
40. Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, Giordano S, Ballinari D, Michieli P, Comoglio PM: Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci USA 1998;95:14379-14383.